Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..
SYS-CON.TV
Today's Top SOA Links


Global Blood Banking And Blood Products Industry

NEW YORK, Dec. 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Blood Banking And Blood Products Industry

http://www.reportlinker.com/p020749/Global-Blood-Banking-And-Blood-Produ...

This report analyzes the worldwide markets for Blood Banking and Blood Products in US$ Million by the following Product Segments: Blood Components and Plasma Products (Whole Blood & Cellular Components, & Plasma Fractions), and Equipment, Blood Tests and Other Consumables (Includes blood screening and related QC function, but excludes patient diagnosis). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 232 companies including leading blood banks such as AABB, America's Blood Centers, American Red Cross, Canadian Blood Services, Japan Red Cross, National Blood Foundation, and New York Blood Center. Some of the leading players in Blood Bank Technology & Supplies also discussed in this report include Beckman Coulter Inc., Becton Dickinson and Company, BioMerieux SA, CSL Behring LLC, Daxor Corporation, Fenwal Inc., Gen-Probe, Inc., Haemonetics Corp, Hemagen Diagnostics Inc., Immucor Inc., Kawasumi Laboratories, Inc., Novartis Vaccines and Diagnostics, Inc., Terumo Corporation, Terumo BCT Inc., ThermoGenesis Corp., and Velico Medical, Inc. Leading Players discussed under the Plasma Fractionation segment include Baxter International Inc., Beijing Tiantan Biological Products Co., Ltd., Bharat Serums, Bio Products Laboratory, Biotest AG, CSL Limited, Grifols, S.A, Guizhou Taibang Biological Products Co., Ltd., Huanlan Biological Engineering Inc., Kedrion S.p.A., Laboratoire Français du Fractionnement et des Biotechnologies, Octapharma AG, OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Sanquin. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Blood Components and Plasma Products I-3Whole Blood & Cellular Components I-4WBCs I-4RBCs I-4Platelets I-4Plasma Fractions I-4Fresh Frozen Plasma I-4Albumin Fractions I-4Factor VIII I-5Factor IX and Factor IX Complex I-5Fibrin/Thrombin I-5Equipment, Blood Tests and Consumables I-5Automated Analyzers for Blood Analysis I-5Blood Tests I-5Consumables I-6II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1

Healthcare Scares Propel the Market II-1

Blood Transfusion Worldwide: A Kaleidoscope of Stark Contrasts II-1

Worldwide Blood Banking and Blood Products Market at a Glance

(All figures are 2012 estimates & CAGR is for the period

2010-2018) II-2

Current and Future Analysis II-2

Analysis by Geographic Region II-2

Analysis by Product Segment II-3

World Blood Components and Plasma Market Analysis in Units II-3

Table 1: World Recent Past, Current & Future Analysis for

Blood Components and Plasma by Region/Country - US, Europe,

Japan, and Rest of World Markets Independently Analyzed with

Annual Consumption in Million Units for Years 2010 through

2018 (includes corresponding Graph/Chart) II-4

Table 2: World 9-Year Perspective for Blood Components andPlasma by Region/Country - Percentage Breakdown of VolumeConsumption for US, Europe, Japan, and Rest of World Marketsfor Years 2010, 2012 & 2018 (includes correspondingGraph/Chart) II-5Red Blood Cells - A Key Blood Component and a Major Contributor II-6Table 3: World Recent Past, Current & Future Analysis for RedBlood Cells by Region/Country - US, Europe, Japan, and Restof World Markets Independently Analyzed with AnnualConsumption in Million Units for Years 2010 through 2018(includes corresponding Graph/Chart) II-6

Table 4: World 9-Year Perspective for Red Blood Cells by

Region/Country - Percentage Breakdown of Volume Consumption

for US, Europe, Japan, and Rest of World Markets for Years

2010, 2012 & 2018 (includes corresponding Graph/Chart) II-7

Blood Plasma Derivatives: An Overview II-7

Blood Plasma Sourcing II-7

Plasma Derived Products: Production II-8

IVIG II-8

Factor VIII II-8

Albumin II-8

Costs Associated with Plasma Derivatives Production II-8

Table 5: Global Plasma Derivatives Market: Percentage

Breakdown of Costs Associated with Production (includes

corresponding Graph/Chart) II-9

Player Scenario II-9

Table 6: Global Plasma Derived Products Market (2011):

Percentage Share Breakdown by Leading Players - Baxter, CSL,

Grifols (incl. Talecris), Octapharma, LFB, Biotest, Kedrion

and Others (includes corresponding Graph/Chart) II-9

Table 7: Global IVIg Market (2011): Percentage Breakdown ofMarket Share for Leading Players (includes correspondingGraph/Chart) II-10Indications Addressed by Major Global IVIg Manufacturers II-10Table 8: Comparative Costs between Plasma Protein Therapiesand Artificially Synthesized Pharmaceuticals (includescorresponding Graph/Chart) II-10

Table 9: Global Plasma Market in the Recent Past (2008):

Market Shares of CSL Behring and Talecris in Select Plasma

Product Markets in terms of Revenues (includes corresponding

Graph/Chart) II-11

Competitive Landscape across Blood Banking, Blood Derived

Products and Plasma Production II-11

Table 10: Leading Players in the Global Blood Screening

Market (2011) (includes corresponding Graph/Chart) II-11

Table 11: Global Blood Derivatives Production (2011):Percentage Share Breakdown of Leading Players - Baxter, CSL,Grifols (incl. Talecris), Octapharma, Novo Nordisk, Bayer,Pfizer, Non-Profit Organizations, and Others (includescorresponding Graph/Chart) II-12

Table 12: Global Blood Plasma Manufacturing Market (2011):

Percentage Share Breakdown by Leading Players - Baxter, CSL,

Grifols (incl. Talecris), Pfizer, Novo Nordisk and Others

(includes corresponding Graph/Chart) II-12

Withdrawal of Octapharma's IVIG Proves Advantageous to

Competitors II-12

2. MARKET TRENDS & ISSUES II-14Key Trends in Blood Banking/Pre-Transfusion Diagnostics II-14Demand Exceeds Supply: Self-Sufficiency is the New Mantra II-14PrIME: An Innovative High-Yield Process to Address Supply Dearth II-14Present State of Plasma Fractionating Industry II-14Plasma Fractionation Industry Concentrated in DevelopedCountries II-15PrIME Tackles the Issue of Currently Unprocessable Plasma II-15New Infections - A Continuous Threat II-15Safety and Availability: The Core Issues II-16Decontamination: A Viable Process II-16New Processes for Safer Blood Supply II-16Diagnostic Innovative Procedures Help Blood Conservation II-17Autologous Transfusion Strapping up for High Growth II-17Enzyme Converted Cells Set to Rule the Industry II-17Blood Unavailability: Substitutes to the Rescue II-17Transfusions: Hospitals Making Way for Others II-18Computer Identification Helps Patients II-18SARS: A Case of Mistaken Identity? II-18Pooling: Economical HIV Testing II-18Private Cord Blood Banking: Flying High Despite Opposition II-19Automation of Blood Banking - Nearing the Efficiency Frontier? II-19Automated Instrumentation Taking the Front Seat II-19Table 13: World Market for Blood Bank Technology (2011):Percentage Breakdown of Revenues by Segment - Manual BloodBag Systems, Automated Systems, Component Lab, CommercialPlasma, Blood Salvage, and Pathogen Inactivation (includescorresponding Graph/Chart) II-20Plasma Market: Automation Making Inroads II-20The RBC Market - Slow to Catch Up II-20Automation of Testing - Yet to Mature II-20Automation to Suffice Shortage Problems II-21How Near to the Efficiency Frontier? II-21

3. PRODUCT OVERVIEW II-22

Blood Banking and Blood Products Industry II-22

Blood Components and Plasma Products II-22

Equipment, Blood Tests and Consumables II-22

Automated Analyzers for Blood Analysis II-22

Blood Tests II-22

Consumables II-23

Blood Collection Equipment II-23

Blood Collection Monitors II-23

Blood Donor Couches II-23

Blood Processing Equipment II-23

Blood Bank Centrifuges II-23

Plasma Thawing II-23

Blood Cell Separators II-24

Blood Storage Equipment II-24

Blood Bags II-24

Platelet Agitators II-24

Blood Bank Refrigerators II-24

Blood - A Primer II-24

Ionic Structure II-24

Blood Components and their Applications II-25

Blood Constituents II-26

Plasma II-26

Red Blood Cells (RBC) II-26

Blood Count II-27

Platelets II-27

White Blood Cells (WBC) II-27

Derivative Products of Blood or Plasma Fractions II-28

Plasma Protein and Fractionation II-28

Plasma Fractionation: Origins and Development II-28

Table 14: Plasma Fractionation Processes: Comparison of

Cohn IVIG and PrIME IVIG Based on Specific Characteristics II-29

The Need II-29

Fresh Frozen Plasma II-29

Other Plasma Fractions II-29

Albumin Fractions II-30

Albumin Usage Rising in Profile, Wastage Worries Run Deep II-30

Immunoglobulins II-30

Immunoglobulin Products Available in the Market (2012) II-30

Table 15: Leading Countries in IVIg Usage Rates in Grams per

1000 Population (includes corresponding Graph/Chart) II-31

Hyper-Immune Immunoglobulin II-31

Factor VIII II-31

Factor IX and Factor IX Complex II-31

Fibrin/Thrombin II-31

Consumption of Blood Based on Type of Surgery/Accident (In

Units) II-32

Table 16: World Market for Plasma Derivatives (2011):

Percentage Breakdown of Revenues by Product Type - IVIG,

Albumin, vWFactor & pdFVIII, Hyperimmunes, A1PI, Poly IG and

Others (includes corresponding Graph/Chart) II-32

Recombinant Products II-32

Development Pipeline of Select rFVIII Products for

Hemophilia A Therapy: Breakdown by Product Name, Developing

Company, State of Development and Expected Market Launch II-33

Table 17: Global Market for Recombinant Hemophilia Therapy

(2011): Percentage Share Breakdown for Leading Players

(includes corresponding Graph/Chart) II-33

Therapeutic Uses of Plasma Products II-33

Albumin Products II-33

Immunoglobulins II-34

Intravenous Immunoglobulin (IVIg) II-34

Normal Immunoglobulin (IMIg) II-34

CMV Immunoglobulin II-34

Hepatitis B Immunoglobulin II-34

Rh (D) Immunoglobulin II-34

Tetanus Immunoglobulin IM II-34

Zoster Immunoglobulin II-35

Table 18: Global Market for Immunoglobulins (IG) (2012):

Percentage Share Breakdown of Leading Products (includes

corresponding Graph/Chart) II-35

Plasma Derived Coagulant Products II-35

Biostate® II-35

Ceprotin® II-35

Factor VII Concentrate II-35

Factor XI Concentrates II-35

Feiba VH® Inhibitor Treatment II-36

Fibrogammin P® II-36

Monofix®-VF II-36

ProthrombinexTM-HT II-36

Thrombotrol®-VF II-36

4. BLOOD COLLECTION METHODS II-37Banking the Natural Blood Resources II-37Blood Banks II-37Blood Banking II-37Blood Transfusion II-37Role of Blood Banks II-37Blood Donor: The Epicenter of the Process II-37Eligibility Criteria for the Donor II-38The Basics of Blood Donation - Myths Exploded & Other Facts II-38Table 19: Active Donors of Whole Blood and Apheresis per1,000 of Population by Country/ Agency (includescorresponding Graph/Chart) II-39

Table 20: Percentage Breakdown of Apheresis and Whole Blood

Donations by Country (includes corresponding Graph/Chart) II-39

Collection Methods II-40

Blood Donation: The Process II-40

Types of Blood Donation II-40

Directed Blood Donations II-40

Autologous Blood Donation II-40

Alternative Usage of Patient's Own Blood II-40

General Blood Donation II-40

Hemodilution II-41

Wound Drainage II-41

Cell Saver II-41

The Method II-41

Blood Salvaging II-41

Blood Collection Centers II-41

Blood Collection Management System II-42

A Historical Retrospective II-42

Blood Collection Centers II-42

Types of Blood Collection Centers II-42

Cord Blood Banks II-42

Profit Collection Centers II-42

Military Blood Banks II-43

Hospital Blood Banks II-43

Community Blood Banks II-43

Non-Profit Collection Centers II-43

Blood Processing II-43

Blood Typing II-44

Rh Blood Group System II-44

ABO Blood Group System II-45

Blood Types and their Compatibility II-45

Table 21: Occurrence of Blood Groups Worldwide (In %)

(includes corresponding Graph/Chart) II-45

Blood Test II-46

Blood Culture II-46

The Costs II-46

History of Blood Banking II-46

5. THE CHANGING LANDSCAPE OF TRANSFUSION TECHNOLOGIES & TESTS II-49Blood Transfusion: A Backdrop II-49Massive Transfusion II-49Complications and Risks Due to Transfusion II-49Circulatory Overload II-50Graft Versus Host Disease (GVHD) II-50Hemolytic Transfusion Reactions II-50Iron Overload II-50Bacterial Contamination II-50Thrombophlebitis II-50Allergic Reactions II-50Air Embolism II-50Hyperkalaemia II-51Changing Role of Blood Banking Technology II-51

6. BLOOD TRANSFUSION: THE PROCESS, TESTS/TECHNOLOGIES II-52

Cross Matching II-52

Blood Donor/Recipient Screening II-52

Blood Typing II-52

Leukoreduction II-52

Leukocyte Reduction Specification Standards/Filters II-53

Coombs Test II-53

7. ALTERNATIVES TO BLOOD TRANSFUSION: A REAL THREAT TO THE INDUSTRY II-54Bloodless Surgery II-54Therapeutic Apheresis II-54Plasmapheresis II-54Plateletpheresis II-54Leukapheresis II-55Volume Expanders II-55Colloids II-55Albumin II-55Dextrans II-55Hydroxyethyl Starch II-55Crystalloids II-55Blood Growth Factor Therapies - Newer Alternatives to Transfusion II-56

8. BLOOD SUBSTITUTES II-57

Blood Substitutes Under Development by Manufacturers II-57

Synthetic Blood Manufacturers/Developers II-58

Alliance Pharmaceuticals Corp. (US) II-58

Biopure Corporation (US) II-58

Enzon Pharmaceuticals (US) II-59

Hemosol Inc. (Canada) II-59

Northfield Laboratories Inc. (US) II-59

Synthetic Blood International, Inc. (US) II-59

9. PRODUCT INNOVATIONS/LAUNCHES IN RECENT PAST - A PERSPECTIVEBUILDER II-60America's Blood Centers Launches Management System for BloodProducts II-60Biomatrica Introduces DNAstable® Blood and DNAgard® Blood forWhole Blood Stabilization at Room Temperature II-60Bio-Rad Launches Fully-Automated IH 1000 Blood Screening System II-60Fenwal Receives US FDA Clearance for Fenwal Amicus® SeparatorSystem II-61BD Unveils BD Microtainer® MAP Microtube II-61Pall Releases Advanced Blood Filter II-62CaridianBCT Rolls Out RBCX Protocol II-62ITL Launches TEGO™ Animal Blood Collection Kit II-63Fenwal to Launch Modified ALYX Kit II-63QIAGEN Launches New QIAsafe DNA Blood Products II-63Gambro Introduces New Prismaflex eXeed™ System II-64AnaSpec Unveils 'SensoLyte® Rh110 Plasmin Activity Assay Kit II-64Typenex® Medical Rolls Out New Barcode Blood Band II-65Olympus Introduces Hemoglobin A1c APT Reagent for ChemistryAnalyzer System II-65BD Diagnostics Launches BD BACTEC™ FX Blood Culture System II-65Beckman Coulter Launches UniCel DxH 800 Coulter® CellularAnalysis System II-66

10. PRODUCT APPROVALS II-67

Quotient Receives FDA Approval for ALBAcyte Reagent RBC Products II-67

EMIT Wins FDA Market Approval for Hypotherm X HX100 Device II-67

MedPro Blood Collection Safety Products Obtain CE Mark II-67

Huaren Pharmaceutical GI and PD Solutions Obtain SFDA Approval II-68

Cerus INTERCEPT Blood System Obtains Approval from Swissmedic II-68

Abbott Obtains BLA Clearance from FDA for ABBOTT PRISM Chagas

Test II-68

CaridianBCT Obtains FDA Approval for New 6.0 Trima Accel®

Automated Blood Collection System II-69

FDA Grants 510(K) Clearance for Expanded Use of Haemonetics II-69

Fenwal Secures FDA Approval for New Platelet Additive Solution II-69

BD Diagnostics Bags FDA Approval for BD Vacutainer® Rapid

Serum Tube II-70

Abbott Obtains FDA Approval for Abbott Prism HIV O Plus Test II-70

11. PRODUCT APPROVALS IN THE RECENT PAST II-72Cerus Receives CE Mark Approval for the INTERCEPT Blood Systemfor Platelets II-72Haemonetics Wins FDA Approval for the ACP 215 System II-72Biomerieux' Polycarbonate BacT/ALERT Receives US FDA Clearance II-72Pall's eBDS Receives Green Signal from FDA II-73CardioPAT™ Surgical Blood Salvage System II-73PCS® 2 - Set to Enhance Plasma Quality II-73Dade Behring's D-Dimer Assay Strapping up for Roll Out II-73

12. RECENT INDUSTRY ACTIVITY II-74

Hologic to Take Over Gen-Probe II-74

ProMetic Obtains New Purchase under Octapharma Agreement II-74

Grifols Takes Over Talecris II-74

IVD Acquisition Acquires Immucor II-75

Nordson Takes Over Value Plastics II-75

American Red Cross Takes Over RBC Collection Assets of HemaCare II-75

Terumo Acquires CaridianBCT II-76

Bioniche to Take Over Plasvacc II-76

Logic Management Consulting to Take Over Guiyang Dalin

Biologic Technologies II-76

Humanwell Healthcare Acquires Further Stake in Zhongyuan Ruide

Bio II-76

Red Cross and Mitsubishi Tanabe to Combine Plasma

Fractionation Business II-77

Fenwal Signs Definitive Agreement with Golden Meditech to Set

Up JV II-77

Fenwal and Biolog-id Enter into Marketing Agreement II-77

GE Healthcare and Neste Jacobs Enter into Partnership II-78

Cerus Enters into Supply Agreement with Etablissement Francais

du Sang II-78

Transfusion Management Services and Vedant Enter into Partnership II-78

Global Healing Collaborates with Partners in Health II-79

ProMetic Expands Strategic Partnership with WIBP II-79

Amunix Partners with Biogen Idec II-80

Fenwal and GenesisBPS Ink Agreement for Blood-Specialty Products II-80

Remi Enters into Collaboration with Barkey for Indian Market II-80

Huaren Pharma to Set Up R&D Center for Blood Purification II-80

China Biologic to Commence Commercial Collection of Plasma at

Ninyang II-81

Grifols to Construct Plasma Fractionation Plant II-81

HLL Lifecare Inaugurates Second Blood Bag Plant in India II-81

13. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-82Pall Inks Distribution Agreement with ASI II-82Cerus Inks Deal with Swiss Red Cross for Deploying INTERCEPTBlood System II-82PT Bio Farma to Construct New Albumin Plant in Indonesia II-82NACO to Establish Plasma Fractionation Facility in Chennai II-82Improve Medical Instruments to Establish Subsidiary in Beijing II-83China Biologic Products Obtains License for Plasma Collectionfrom Shandong Province Health Department II-83Sorin Group Sells Two Non-Core Product Lines to Cytomedix II-83Sigma to Lease QC Manager Software to New Orleans based BloodCenter II-83CaridianBCT's PRT System Chosen by Polish Health Ministry II-84Micronics Obtains FDA Approval to Market ABORhCard II-84HemaCare Signs Two New Blood Service Contracts II-84Haemonetics Gains Rights to Alba's Full Line of Blood TypingReagents II-85American Red Cross Inks 3-Year Deal with ITL II-85Daxor's Idant Labs Bags Blood Banking Contract from RMSB&G II-85Beckman Coulter Agrees to Distribute CellaVision DigitalMorphology Products II-86Haemonetics Takes Over Global Med II-86Therapure Biopharma Inks Long Term Pact with LFB Biomedicaments II-86MRHC Obtains License for SafeTrace Tx Solution of Global Med II-87Life Technologies to Acquire AcroMetrix II-87Heska Enters into a Supply Agreement with Roche Diagnostics II-87BLOOD Bank of Alaska Obtains License for Mediware's LifeTrakTechnology II-88Europe and the US Expand Blood Banking Agreement II-88Pfizer Acquires Wyeth II-89Baxter Inaugurates New BLOOD Plasma Fractionation Facility inVienna II-89ProMetic Acquires Majority Shareholding in PRDT II-89China Biologic to Collaborate with IBT on Research & Development II-90Gen-Probe to Establish Independent New Firm for IndustrialTesting II-90Haemonetics Acquires SEBRA Blood Collection & Processing Unit II-91Beckman Coulter Acquires Lab Based Diagnostics Business ofOlympus II-92Golden Meditech and Fenwal to Establish a Blood CollectionJoint Venture in China II-92PRCS Inaugurates State-of-the-Art Blood Bank II-92CSL and Talecris Terminate Merger Agreement II-93Immucor Inks 5-Year Deal with Alverno II-93Gen-Probe Acquires Tepnel and Renews Partnership with Novartis II-94Haemonetics Takes Over Neoteric Technology II-94Haemonetics Acquires Altivation Software II-95PacifiCord Sets Up Cord Blood Banking Facility in Irvine II-95China Biologic Acquires 35% Stake in Xi`an Huitian Blood Products II-95Octapharma Plans to Set Up Fractionation Facility in Poland II-96Therapure BioPharma Inks Development Services Deal with LFBBiotechnologies II-96Biotest Acquires Blood Plasma Collection Center from Talecris II-96Gen-Probe Expands and Extends Blood Screening Alliance withNovartis II-96Celestial Biologicals Collaborates with GE Healthcare forIndian Market II-97

14. FOCUS ON SELECT GLOBAL PLAYERS II-98

Leading Blood Banks II-98

AABB (US) II-98

America's Blood Centers (US) II-98

American Red Cross (US) II-98

Canadian Blood Services (Canada) II-99

Japan Red Cross Society (Japan) II-99

National Blood Foundation (US) II-99

New York Blood Center (US) II-100

Leading Players in Blood Bank Technology and Supplies II-100

Beckman Coulter, Inc. (US) II-100

Becton, Dickinson and Company (US) II-100

BioMerieux SA (France) II-101

CSL Behring LLC (US) II-101

Daxor Corporation (US) II-101

Fenwal Inc. (US) II-102

Gen-Probe, Inc. (US) II-102

Haemonetics Corporation (US) II-102

Hemagen Diagnostics Inc. (US) II-103

Immucor Inc. (US) II-103

Kawasumi Laboratories, Inc. (Japan) II-104

Novartis Vaccines and Diagnostics, Inc (US) II-104

Terumo Corp. (Japan) II-105

Terumo BCT Inc (US) II-105

ThermoGenesis Corp. (US) II-105

Velico Medical, Inc. (US) II-106

Leading Players in Plasma Fractionation II-106

Baxter International Inc. (US) II-106

Beijing Tiantan Biological Products Co., Ltd (China) II-106

Bharat Serums and Vaccines Ltd (India) II-106

Bio Products Laboratory Ltd (UK) II-107

Biotest AG (Germany) II-107

CSL Limited (Australia) II-107

Grifols, S.A (Spain) II-108

Guizhou Taibang Biological Products Co., Ltd (China) II-108

Huanlan Biological Engineering Inc. (China) II-109

Kedrion S.p.A. (Italy) II-109

Laboratoire Français du Fractionnement et des Biotechnologies

(France) II-109

Octapharma AG (Switzerland) II-109

OMRIX Biopharmaceuticals Ltd (Israel) II-110

Shanghai RAAS Blood Products Co., Ltd. (China) II-110

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China) II-110

Sanquin (The Netherlands) II-110

15. GLOBAL MARKET PERSPECTIVE II-111Table 22: World Recent Past, Current & Future Analysis forBlood Banking and Blood Products by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific (excluding Japan), LatinAmerica and Rest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2010 through2018 (includes corresponding Graph/Chart) II-111

Table 23: World Historic Review for Blood Banking and Blood

Products by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-112

Table 24: World 15-Year Perspective for Blood Banking andBlood Products by Geographic Region - Percentage Breakdown ofValue Sales for US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World Markets forYears 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-113Blood Banking and Blood Products Market by Product Group/Segment II-114Table 25: World Recent Past, Current & Future Analysis forBlood Components and Plasma Products by Geographic Region -US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),Latin America and Rest of World Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2010through 2018 (includes corresponding Graph/Chart) II-114

Table 26: World Historic Review for Blood Components and

Plasma Products by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-115

Table 27: World 15-Year Perspective for Blood Components andPlasma Products by Geographic Region - Percentage Breakdown ofValue Sales for US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World Markets forYears 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-116

Table 28: World Recent Past, Current & Future Analysis for

Blood Components and Plasma Products by Product Segment -

Whole Blood & Cellular Components, and Plasma Fractions

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) II-117

Table 29: World Historic Review for Blood Components andPlasma Products by Product Segment - Whole Blood & CellularComponents, and Plasma Fractions Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years2004 through 2009 (includes corresponding Graph/Chart) II-118

Table 30: World 15-Year Perspective for Blood Components and

Plasma Products by Product Segment - Percentage Breakdown of

Value Sales for Whole Blood & Cellular Components, and Plasma

Fractions Markets for Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) II-119

Table 31: World Recent Past, Current & Future Analysis forWhole Blood & Cellular Components by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific (excluding Japan), LatinAmerica and Rest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2010 through2018 (includes corresponding Graph/Chart) II-120

Table 32: World Historic Review for Whole Blood & Cellular

Components by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) II-121

Table 33: World 15-Year Perspective for Whole Blood & CellularComponents by Geographic Region - Percentage Breakdown ofValue Sales for US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World Markets forYears 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-122

Table 34: World Recent Past, Current & Future Analysis for

Plasma Fractions by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) II-123

Table 35: World Historic Review for Plasma Fractions byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includes correspondingGraph/Chart) II-124

Table 36: World 15-Year Perspective for Plasma Fractions by

Geographic Region - Percentage Breakdown of Value Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2004, 2011 &

2018 (includes corresponding Graph/Chart) II-125

Table 37: World Recent Past, Current & Future Analysis forEquipment, Blood Tests and Other Consumables by GeographicRegion - US, Canada, Japan, Europe, Asia-Pacific (excludingJapan), Latin America and Rest of World Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years2010 through 2018 (includes corresponding Graph/Chart) II-126

Table 38: World Historic Review for Equipment, Blood Tests and

Other Consumables by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-127

Table 39: World 15-Year Perspective for Equipment, Blood Testsand Other Consumables by Geographic Region - PercentageBreakdown of Value Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), Latin America and Rest ofWorld Markets for Years 2004, 2011 & 2018 (includescorresponding Graph/Chart) (includes correspondingGraph/Chart) II-128III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current and Future Analysis III-1

Table 40: Blood and Organ Banks in the US (2011):

Percentage Share Breakdown of Revenues for Major Players -

American Red Cross, Musculoskeletal Transplant Foundation

Inc., Community Blood Center and Community Tissue Services

and CSL Ltd. (includes corresponding Graph/Chart) III-1

Table 41: US Blood Bank Industry (2011): Percentage ShareBreakdown by Major Blood Suppliers (includes correspondingGraph/Chart) III-2Market Trends III-2Recession Impacts Blood Bank Reserves III-2US Blood Collection & Supply Profile III-2Blood Group Distribution III-3Table 42: US Market for Blood Banking and Blood Products:Percentage Break up of Blood Group by Rh Factor (includescorresponding Graph/Chart) III-3

Table 43: Percentage Break up of Rh Blood Types in the US

by Racial Group (includes corresponding Graph/Chart) III-4

Blood Donated and Transfused Every Year III-4

Males Form the Major Chunk of Donors III-4

Cost of Blood III-4

SARS Scares: Blood Banks Feel the Heat III-4

Blood and Blood Preparations: A Review of Trade Statistics III-5

Table 44: US Blood and Blood Preparations Market (2010 &

2011): Percentage Breakdown of Value Imports by Country of

Origin for Germany, UK, Canada, Switzerland, Belgium and

Others (includes corresponding Graph/Chart) III-5

Table 45: US Blood and Blood Preparations Market (2010 &2011): Percentage Breakdown of Value Exports by Destinationfor UK, Germany, Canada, Netherlands, Belgium and Others(includes corresponding Graph/Chart) III-6

Table 46: US Market for Globulins (2011): Percentage

Breakdown by Leading Players for Baxter, Grifols (incl.

Talecris), CSL and Octapharma (includes corresponding

Graph/Chart) III-6

US Blood Components and Plasma Market Analysis in Units III-7

Table 47: US Recent Past, Current & Future Analysis for

Blood Components and Plasma by Product Category - Red Blood

Cells (RBCs), Platelets, and Fresh Frozen Plasma Markets

Independently Analyzed with Annual Consumption in Million

Units for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-7

Table 48: US Historic Review for Blood Components andPlasma by Product Category - Red Blood Cells (RBCs),Platelets, and Fresh Frozen Plasma Markets IndependentlyAnalyzed with Annual Consumption in Million Units for Years2004 through 2009 (includes corresponding Graph/Chart) III-8

Table 49: US 15-Year Perspective for Blood Components and

Plasma by Product Category - Percentage Breakdown of Volume

Consumption for Red Blood Cells (RBCs), Platelets, and

Fresh Frozen Plasma for Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-8

Regulations Control Plasma Collection Industry III-9

Product launch III-9

Strategic Corporate Developments III-9

Key players III-13

B.Market Analytics III-21

Table 50: US Recent Past, Current & Future Analysis for

Blood Banking and Blood Products by Product Group/Segment -

Blood Components and Plasma Products (Whole Blood & Cellular

Components, and Plasma Fractions); and Equipment, Blood

Tests and Other Consumables Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-21

Table 51: US Historic Review for Blood Banking and BloodProducts by Product Group/ Segment - Blood Components andPlasma Products (Whole Blood & Cellular Components, andPlasma Fractions); and Equipment, Blood Tests and OtherConsumables Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-22

Table 52: US 15-Year Perspective for Blood Banking and Blood

Products by Product Group/ Segment - Percentage Breakdown of

Value Sales for Blood Components and Plasma Products (Whole

Blood & Cellular Components, and Plasma Fractions); and

Equipment, Blood Tests and Other Consumables Markets for

Years 2004, 2011 & 2018 (includes corresponding Graph/Chart) III-23

2. CANADA III-24A.Market Analysis III-24Current and Future Analysis III-24Blood Facts III-24Bleeding Disorders - A Major Threat III-24'CSA-Z902-04' - A Comprehensive Voluntary Blood Safety Standard III-24Blood and Blood Preparations: Import & Export Scenario III-25Table 53: Canadian Blood and Blood Preparations Market(2010 & 2011): Percentage Breakdown of Value Imports byCountry of Origin for US, Switzerland, Germany,Netherlands, UK and Other Countries (includes correspondingGraph/Chart) III-25

Table 54: Canadian Blood and Blood Preparations Market

(2010 & 2011): Percentage Breakdown of Value Exports by

Destination for US, France, UK, Japan, Australia and Other

Countries (includes corresponding Graph/Chart) III-26

Strategic Corporate Development III-26

Canadian Blood Services - the Major Blood Bank III-27

B.Market Analytics III-28

Table 55: Canadian Recent Past, Current & Future Analysis

for Blood Banking and Blood Products by Product

Group/Segment - Blood Components and Plasma Products (Whole

Blood & Cellular Components, and Plasma Fractions); and

Equipment, Blood Tests and Other Consumables Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-28

Table 56: Canadian Historic Review for Blood Banking andBlood Products by Product Group/ Segment - Blood Componentsand Plasma Products (Whole Blood & Cellular Components, andPlasma Fractions); and Equipment, Blood Tests and OtherConsumables Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-29

Table 57: Canadian 15-Year Perspective for Blood Banking and

Blood Products by Product Group/Segment - Percentage

Breakdown of Value Sales for Blood Components and Plasma

Products (Whole Blood & Cellular Components, and Plasma

Fractions); and Equipment, Blood Tests and Other Consumables

Markets for Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-30

3. JAPAN III-31A.Market Analysis III-31Current and Future Analysis III-31Japan Witnesses Surge in Imported Blood Products III-31Growing Market for Fresh Frozen Plasma III-31Growing Use of Imported Albumin Based Blood Products III-31The Goal of Self-Sufficiency III-32Strategic Corporate Development III-33Key players III-33B.Market Analytics III-35Table 58: Japanese Recent Past, Current & Future Analysisfor Blood Banking and Blood Products by ProductGroup/Segment - Blood Components and Plasma Products (WholeBlood & Cellular Components, and Plasma Fractions); andEquipment, Blood Tests and Other Consumables MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-35

Table 59: Japanese Historic Review for Blood Banking and

Blood Products by Product Group/ Segment - Blood Components

and Plasma Products (Whole Blood & Cellular Components, and

Plasma Fractions); and Equipment, Blood Tests and Other

Consumables Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) III-36

Table 60: Japanese 15-Year Perspective for Blood Banking andBlood Products by Product Group/Segment - PercentageBreakdown of Value Sales for Blood Components and PlasmaProducts (Whole Blood & Cellular Components, and PlasmaFractions); and Equipment, Blood Tests and Other ConsumablesMarkets for Years 2004, 2011 & 2018 (includes correspondingGraph/Chart) III-37

4. EUROPE III-38

A.Market Analysis III-38

Current and Future Analysis III-38

European Blood Banking and Blood Products Market at a

Glance (All figures are 2012 estimates & CAGR is for the

period 2010-2018) III-38

Market Trends and Issues III-39

Legislations on Payment for Donation Restrict Donors III-39

Government's Check on Healthcare Costs Pressurizes BCT

Manufacturers III-39

Purchasing System Witnesses Modifications III-39

EU Nations Marching Towards Self-Sufficiency in Blood and

Blood Products III-39

Blood Banking Devices Market III-39

Table 61: European Recent Past, Current & Future Analysis

for Blood Banking Devices - Manual Blood Collection,

Apheresis, and Autologous Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-40

Table 62: European Historic Review for Blood BankingDevices - Manual Blood Collection, Apheresis, andAutologous Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2004 through 2009(includes corresponding Graph/Chart) III-41

Table 63: European 15-Year Perspective for Blood Banking

Devices - Percentage Breakdown of Value Sales for Manual

Blood Collection, Apheresis, and Autologous Markets for

Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-42

Table 64: European Blood Banking Devices Market (2012):Percentage Breakdown of Value Sales by Geographic Regionfor France, Germany, Italy, UK, Spain and Rest of Europe(includes corresponding Graph/Chart) III-42A Snapshot of Health Care Systems Across Select EU Countries III-43France III-43Germany III-43Italy III-43The UK III-43Spain III-43B.Market Analytics III-44Table 65: European Recent Past, Current & Future Analysisfor Blood Banking and Blood Products by Geographic Region -France, Germany, Italy, UK, Spain, Russia, and Rest ofEurope Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2010 through 2018 (includescorresponding Graph/Chart) III-44

Table 66: European Historic Review for Blood Banking and

Blood Products by Geographic Region - France, Germany,

Italy, UK, Spain, Russia, and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) III-45

Table 67: European 15-Year Perspective for Blood Banking andBlood Products by Geographic Region - Percentage Breakdownof Value Sales for France, Germany, Italy, UK, Spain, Russiaand Rest of Europe Markets for Years 2004, 2011 & 2018(includes corresponding Graph/Chart) III-46

Table 68: European Recent Past, Current & Future Analysis

for Blood Banking and Blood Products by Product

Group/Segment - Blood Components and Plasma Products (Whole

Blood & Cellular Components, and Plasma Fractions); and

Equipment, Blood Tests and Other Consumables Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-47

Table 69: European Historic Review for Blood Banking andBlood Products by Product Group/Segment - Blood Componentsand Plasma Products (Whole Blood & Cellular Components, andPlasma Fractions); and Equipment, Blood Tests and OtherConsumables Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-48

Table 70: European 15-Year Perspective for Blood Banking and

Blood Products by Product Group/ Segment - Percentage

Breakdown of Value Sales for Blood Components and Plasma

Products (Whole Blood & Cellular Components, and Plasma

Fractions); and Equipment, Blood Tests and Other Consumables

Markets for Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-49

4a. FRANCE III-50A.Market Analysis III-50Current and Future Analysis III-50Strategic Corporate Development III-50Key players III-50B.Market Analytics III-52Table 71: French Recent Past, Current & Future Analysis forBlood Banking and Blood Products by Product Group/Segment -Blood Components and Plasma Products (Whole Blood & CellularComponents, and Plasma Fractions); and Equipment, BloodTests and Other Consumables Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2010through 2018 (includes corresponding Graph/Chart) III-52

Table 72: French Historic Review for Blood Banking and Blood

Products by Product Group/Segment - Blood Components and

Plasma Products (Whole Blood & Cellular Components, and

Plasma Fractions); and Equipment, Blood Tests and Other

Consumables Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) III-53

Table 73: French 15-Year Perspective for Blood Banking andBlood Products by Product Group/ Segment - PercentageBreakdown of Value Sales for Blood Components and PlasmaProducts (Whole Blood & Cellular Components, and PlasmaFractions); and Equipment, Blood Tests and Other ConsumablesMarkets for Years 2004, 2011 & 2018 (includes correspondingGraph/Chart) III-54

4b. GERMANY III-55

A.Market Analysis III-55

Current and Future Analysis III-55

Biotest AG - A Key Player III-55

B.Market Analytics III-56

Table 74: German Recent Past, Current & Future Analysis for

Blood Banking and Blood Products by Product Group/Segment -

Blood Components and Plasma Products (Whole Blood & Cellular

Components, and Plasma Fractions); and Equipment, Blood

Tests and Other Consumables Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-56

Table 75: German Historic Review for Blood Banking and BloodProducts by Product Group/ Segment - Blood Components andPlasma Products (Whole Blood & Cellular Components, andPlasma Fractions); and Equipment, Blood Tests and OtherConsumables Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2004 through 2009 (includ

To order this report:Blood_Supply,_Tissue_Banking_and_Transplantation Industry: Global Blood Banking And Blood Products Industry

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers
ADS BY GOOGLE